(Fixes typo in company name in headline and paragraph 1)
April 30 (Reuters) – A panel of outside experts to the U.S. Food and Drug Administration voted against backing the risk-benefit profile of AstraZeneca’s breast cancer drug, the company said on Thursday.
(Reporting by Sri Hari N S in Bengaluru)
